var data={"title":"Beclomethasone (nasal): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Beclomethasone (nasal): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387716?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=beclomethasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (nasal): Drug information&quot;</a> and <a href=\"topic.htm?path=beclomethasone-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Beclomethasone (nasal): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990246\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Beconase AQ;</li>\n      <li>Qnasl;</li>\n      <li>Qnasl Childrens</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990247\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Beclomethasone;</li>\n      <li>Mylan-Beclo AQ;</li>\n      <li>Rivanase AQ</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10470857\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Intranasal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10473424\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=beclomethasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Product formulations are not interchangeable: Beconase AQ: One spray delivers 42 mcg; Qnasl: One spray delivers 40 mcg or 80 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic rhinitis:</b> Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Beconase AQ (42 mcg/spray):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to &lt;12 years: Initial: 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily); if response inadequate, may increase to 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily); once symptoms are adequately controlled, decrease dose to 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 1 or 2 sprays (42 mcg or 84 mcg) <b>per nostril</b> twice daily (total dose: 168 to 336 mcg daily); maximum daily dose: 336 mcg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Qnasl:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to &lt;12 years: Qnasl 40 mcg: 1 spray (40 mcg) <b>per nostril</b> once daily (total dose: 80 mcg/day); maximum daily dose: 80 mcg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Qnasl 80 mcg: 2 sprays (160 mcg) <b>per nostril</b> once daily (total daily dose: 320 mcg/day); maximum daily dose: 320 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal airway obstruction/adenoidal hypertrophy:</b> Limited data available; dosing regimens variable: Intranasal: Beconase AQ (42 mcg/spray): Children 5 to 12 years: Initial: 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily) for 4 weeks, followed by 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily). Dosing based on a double-blind, placebo-controlled crossover study (n=17, age range: 5 to 11 years); results showed significant reduction in adenoid hypertrophy and related obstructive nasal symptoms following 4 weeks of beclomethasone therapy vs placebo (Demain 1995). Positive efficacy findings were also observed in a single-blind, placebo-controlled crossover study of 53 children (mean age: 3.8 &plusmn; 1.3 years) using a total daily dose of 400 mcg/day (200 mcg twice daily [using 50 mcg/spray formulation, not available in US]) delivered as 100 mcg (2 sprays) <b>per nostril</b> twice daily (Criscuoli 2003). Lower daily dosage (200 mcg/day) have not been found effective (Lepcha 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal polyps (postsurgical prophylaxis), vasomotor rhinitis:</b> Intranasal: Beconase AQ (42 mcg/spray):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: Initial: 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily); if response inadequate, may increase to 2 sprays (84 mcg) <b>per nostril</b> twice daily (total dose: 336 mcg daily); once symptoms are adequately controlled, decrease dose to 1 spray (42 mcg) <b>per nostril</b> twice daily (total dose: 168 mcg daily).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;12 years: 1 or 2 sprays (42 mcg or 84 mcg) <b>per nostril</b> twice daily (total dose: 168 to 336 mcg daily); maximum daily dose: 336 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic rhinitis:</b> Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Beconase AQ: 1 or 2 inhalations (42 or 84 mcg) in each nostril twice daily; total dose: 168 to 336 mcg daily; maximum dose: 336 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Qnasl 80 mcg: 2 inhalations (160 mcg) in each nostril once daily (maximum: 320 mcg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal polyps (postsurgical prophylaxis), vasomotor rhinitis:</b> Intranasal: Beconase AQ: 1 or 2 inhalations (42 or 84 mcg) in each nostril twice daily; total dose: 168 to 336 mcg daily; maximum dose: 336 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991835\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Nasal, as dipropionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qnasl: 80 mcg/actuation (8.7 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Qnasl Childrens: 40 mcg/actuation (4.9 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as dipropionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Beconase AQ: 42 mcg/spray (25 g) [contains benzalkonium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990249\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005920\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=beclomethasone-nasal-drug-information\" class=\"drug drug_general\">see &quot;Beclomethasone (nasal): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beconase AQ 25 g canisters contain 180 sprays.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Qnasl 4.9 g canisters contains 60 actuations, and the 8.7 g canisters contain 120 actuations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10473462\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Shake well prior to each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the &quot;discard by&quot; date or after labeled number of doses has been used, even if bottle is not completely empty. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beconase AQ: Prior to initial use, prime pump 6 times (or until fine spray appears); repeat priming if product not used for &ge;7 days. Nasal applicator and dust cap may be washed in warm water and dried thoroughly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Qnasl: Prior to initial use, prime pump 4 times. If product not used for &ge;7 days, prime pump 2 times. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991716\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Beconase AQ: Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Qnasl: Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not puncture. Do not store near heat or open flame. Do not expose to temperatures higher than 49&deg;C (120&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10470858\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beconase AQ: Management of nasal symptoms associated with seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevention of recurrence of nasal polyps following surgical removal (FDA approved in ages &ge;6 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Qnasl:  Management of nasal symptoms associated with seasonal and perennial allergic rhinitis (FDA approved in ages &ge;4 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal corticosteroids have also been used as an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis primarily in patients with history of allergic rhinitis (Chow 2012), in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (Marcus 2012), and for children with nasal obstruction caused by adenoidal hypertrophy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991709\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal suppression (at high doses or in susceptible individuals), hypercorticoidism (at high doses or in susceptible individuals)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, oral candidiasis (rare; more likely with aqueous solution)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Decreased linear skeletal growth rate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Intraocular pressure increased, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis, nasal candidiasis (rare; more likely with aqueous solution), nasal congestion, nasal mucosa irritation (erosion), nasopharyngitis (more common in adults), pharyngeal candidiasis (rare; more likely with aqueous solution), rhinorrhea, sneezing, upper respiratory tract infection (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children), wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Ageusia, altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, anosmia, blurred vision, bronchospasm, burning sensation, cataract, chorioretinitis, dry nose, glaucoma, hypersensitivity reaction, nasal mucosa ulcer, nasal septum perforation, skin rash, unpleasant taste, urticaria, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991691\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to beclomethasone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for intranasal steroids is limited. However, the possibility of cross-sensitivity cannot be ruled out with certainty because of similarities in chemical structure and/or pharmacologic actions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Active or quiescent tuberculosis or untreated fungal, bacterial and viral infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991692\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, urticaria, and wheezing) have been reported; discontinue for severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infections, mask an acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines; avoid exposure to chickenpox and/or measles, especially if not immunized. Avoid use or use with caution in patients with latent/active tuberculosis, untreated bacterial or fungal infections (local or systemic), viral or parasitic infections, or ocular herpes simplex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Nasal septal perforation and localized Candida albicans infections of the nose and/or pharynx may occur. Nasal discomfort, epistaxis, and nasal ulceration may also occur; periodically examine nasal mucosa in patients on long-term therapy. Monitor patients for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Increased intraocular pressure, open-angle glaucoma, and/or cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Rhinitis: Do not use in the presence of untreated localized infection involving the nasal mucosa. Do not continue use beyond 3 weeks in the absence of significant symptomatic improvement. Symptomatic relief may not occur for as long as 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Nasal polyps: Treatment may need to be continued for several weeks or more before a therapeutic result can be fully assessed. Treatment of nasal polyps with beclomethasone should be considered adjunctive therapy to surgical removal and/or the use of other medications that will permit effective penetration of beclomethasone into the nose. Recurrence can occur after stopping treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298818\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9770054\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15947&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Nasal) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991686\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991687\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intranasal corticosteroids may be acceptable for the treatment of rhinitis during pregnancy when used at recommended doses (Lal 2016; Wallace 2008). Pregnant females adequately controlled on beclomethasone may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females and less systemic absorption may be preferred (Alhussien 2017; Namazy 2016; Wallace 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10473463\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991717\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991772\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within a few days up to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Beclomethasone dipropionate (BDP): 20 L; Beclomethasone-17-monopropionate (17-BMP): 424 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: BDP 87%; 17-BMP: 94% to 96% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: BMP is a prodrug (inactive); undergoes rapid conversion to 17-BMP (major active metabolite) during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 17-BMP: 44% (43% from swallowed portion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: BDP: 0.5 hours; 17-BMP: 2.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (60%); urine (&lt;10% to 12%; as free and conjugated metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10473465\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">When used short term as adjunctive therapy in acute bacterial rhinosinusitis (ABRS), intranasal steroids show modest symptomatic improvement and few adverse effects; improvement is primarily due to increased sinus drainage. Use should be considered optional in ABRS; however, intranasal corticosteroids should be routinely prescribed to ABRS patients who have a history of or concurrent allergic rhinitis (Chow 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7991837\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Qnasl Childrens Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/ACT (4.9 g): $251.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Qnasl Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/ACT (8.7 g): $251.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Beconase AQ Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">42 mcg/spray (25 g): $352.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961957\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AeroBec (DK, NO, SE);</li>\n      <li>Aerocort (MY);</li>\n      <li>Aerovent (IN);</li>\n      <li>Afifon (IL);</li>\n      <li>Alanase (NZ, TW);</li>\n      <li>Aldecin (BG);</li>\n      <li>Aquanase (MY);</li>\n      <li>Asmabec (IE);</li>\n      <li>Atomase (NZ);</li>\n      <li>Beclate (HK, IN, LK, MY, ZA);</li>\n      <li>Beclazone (HK, NZ);</li>\n      <li>Beclo-Asma CFC Free (SG);</li>\n      <li>Beclo-Rhino (FR);</li>\n      <li>Beclo-Rino (ES);</li>\n      <li>Becloforte (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Beclomate NS (LK);</li>\n      <li>Beclomet (CH, DK, FI, MY, NO, SE, SG, TW);</li>\n      <li>Beclomet Easyhaler (TH);</li>\n      <li>Beclomin (PK);</li>\n      <li>Beclonasal (EE, FI, HU);</li>\n      <li>Beclone (FR);</li>\n      <li>Beclophar (GB);</li>\n      <li>Beclosol Aquoso (BR);</li>\n      <li>Beclovent Inhalador (CO);</li>\n      <li>Beconase (AE, AT, BB, BF, BH, BJ, BM, BS, CH, CI, CO, CR, CY, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GT, GY, HN, IQ, IR, JM, JO, KE, KW, LR, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PK, PR, PT, QA, SA, SC, SD, SL, SN, SV, SY, TH, TN, TT, TZ, UG, VE, YE, ZA, ZM, ZW);</li>\n      <li>Beconase Allergy &amp; Hayfever 12 Hour (AU);</li>\n      <li>Becotide (AE, AT, BE, BF, BG, BH, BJ, CI, CR, CY, CZ, DO, EE, ET, FR, GB, GH, GM, GN, GT, HK, HN, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NI, NO, OM, PA, PT, QA, RU, SA, SC, SD, SG, SK, SL, SN, SV, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Belax (MY);</li>\n      <li>Bemase (TH);</li>\n      <li>Bemedrex Easyhaler (FR);</li>\n      <li>Bronconox (CO);</li>\n      <li>Bronconox Forte (CO);</li>\n      <li>Ciplametazon Inhalador Nasal (CO);</li>\n      <li>Clenil (AE, AR, BH, BR, CY, EG, IL, IQ, IR, IT, JO, KW, LB, LK, LY, OM, QA, SA, SG, SY, TW, YE);</li>\n      <li>Clenil Forte (ID);</li>\n      <li>Clenil Modulite (GB);</li>\n      <li>Clipper (BE, GB);</li>\n      <li>Decomit (BD, LK, SG);</li>\n      <li>Destap (CL);</li>\n      <li>Easyhaler Beclomethasone (GB, IE);</li>\n      <li>Eclosynt (CO);</li>\n      <li>Ecobec (BG, EE, FR, PT);</li>\n      <li>Nasair (VE);</li>\n      <li>Nasobec (IE, MT);</li>\n      <li>Nasobec Aqueous (GR, HK, KR, PL);</li>\n      <li>Neconase (CN);</li>\n      <li>Nexxair (FR);</li>\n      <li>Oxiplus (PY);</li>\n      <li>Oxiplus SF (UY);</li>\n      <li>Propavent (AR);</li>\n      <li>Q Var (CH, CR, DO, GB, GT, HN, MY, NI, NZ, PA, PT, SV, TH);</li>\n      <li>Qvar Autohaler (AU, FR);</li>\n      <li>Qvar Inhaler (AU);</li>\n      <li>Respocort (NZ);</li>\n      <li>Rhino Clenil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Rhinomaxil (FR);</li>\n      <li>Rino-Clenil (KR, TH);</li>\n      <li>Rinoclenil (RO);</li>\n      <li>Rinosol (PY, TR);</li>\n      <li>Steradin (BD);</li>\n      <li>Ventolair (DE);</li>\n      <li>Viarex (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline For Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Criscuoli G, D'Amora S, Ripa G, et al, &quot;Frequency of Surgery Among Children Who Have Adenotonsillar Hypertrophy and Improve After Treatment With Nasal Beclomethasone,&quot; <i>Pediatrics</i>, 2003, 111(3):e236-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/12612277/pubmed\" target=\"_blank\" id=\"12612277\">12612277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Demain JG and Goetz DW, &ldquo;Pediatric Adenoidal Hypertrophy and Nasal Airway Obstruction: Reduction With Aqueous Nasal Beclomethasone,&rdquo; <i>Pediatrics</i>, 1995, 95(3):355-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/7862473/pubmed\" target=\"_blank\" id=\"7862473\">7862473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepcha A, Kurien M, Job A, et al, &quot;Chronic Adenoid Hypertrophy in Children - Is Steroid Nasal Spray Beneficial?&quot; <i>Indian J Otolaryngol Head Neck Surg</i>, 2002, 54(4):280-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/23119911/pubmed\" target=\"_blank\" id=\"23119911\">23119911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcus CL, Brooks LJ, Draper KA, et al, &quot;Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome,&quot; <i>Pediatrics</i>, 2012, 130(3):576-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/22926173/pubmed\" target=\"_blank\" id=\"22926173\">22926173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/beclomethasone-nasal-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15947 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7990246\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7990247\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10470857\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10473424\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7991835\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F7990249\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005920\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10473462\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7991716\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10470858\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7991709\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7991691\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7991692\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298818\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9770054\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7991686\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7991687\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10473463\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7991717\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F7991772\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10473465\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7991837\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961957\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15947|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=beclomethasone-nasal-drug-information\" class=\"drug drug_general\">Beclomethasone (nasal): Drug information</a></li><li><a href=\"topic.htm?path=beclomethasone-nasal-patient-drug-information\" class=\"drug drug_patient\">Beclomethasone (nasal): Patient drug information \t</a></li></ul></div></div>","javascript":null}